Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy.

ABSTRACT:

Background

Niraparib is approved for maintenance treatment of tubo-ovarian cancer patients, but data on older patients are limited. This retrospective study evaluated its safety and efficacy in primary advanced tubo-ovarian cancer, focusing on patients ≥ 75 years.

Methods

Women aged ≥ 50 years diagnosed with primary high-grade serous tubo-ovarian cancer, treated with niraparib between 2019-2023, were enrolled. Patients were stratified into three groups: A (50-64 years), B (65-74 years), and C (≥ 75 years). The primary outcome was progression-free survival. The secondary outcomes were toxicity and dose reduction.

Results

127 patients were identified: 62 (48.8%) group A, 26 (20.5%) group B, and 39 (30.7%) group C. Baseline characteristics were comparable across groups,

SUBMITTER: Apostol AI 

PROVIDER: S-EPMC12644187 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature